Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.40.

RVPH has been the topic of a number of research reports. D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, January 21st. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price objective on the stock. HC Wainwright lowered their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Friday, January 10th. Finally, Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 10th.

Reviva Pharmaceuticals Stock Down 2.5 %

Reviva Pharmaceuticals stock opened at $1.15 on Friday. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.28. The firm’s fifty day moving average is $1.76 and its 200 day moving average is $1.48. The company has a market capitalization of $38.46 million, a PE ratio of -1.04 and a beta of -0.09.

Institutional Trading of Reviva Pharmaceuticals

Several institutional investors have recently made changes to their positions in RVPH. Raymond James Financial Inc. bought a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth $25,000. Cornerstone Select Advisors LLC bought a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth $32,000. Drive Wealth Management LLC bought a new position in Reviva Pharmaceuticals during the fourth quarter valued at about $36,000. XTX Topco Ltd bought a new position in Reviva Pharmaceuticals during the fourth quarter valued at about $45,000. Finally, Tower Research Capital LLC TRC grew its position in Reviva Pharmaceuticals by 848.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after buying an additional 23,953 shares during the period. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.